MODIFICATION
A -- Combating Antibiotic-Resistant Bacteria (CARB)
- Notice Date
- 4/20/2017
- Notice Type
- Modification/Amendment
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of the Army, U.S. Army Medical Research Acquisition Activity, U.S. Army Medical Research Acquisition Activity, Attn: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014, Maryland, 21702-5014, United States
- ZIP Code
- 21702-5014
- Solicitation Number
- RPI-17-04-CARB
- Archive Date
- 5/27/2017
- Point of Contact
- Lisa A. Fisher, Phone: 843-760-3356
- E-Mail Address
-
lisa.fisher@ati.org
(lisa.fisher@ati.org)
- Small Business Set-Aside
- N/A
- Description
- MTEC is excited to announce a Request for Project Information (RPI) focused on the development of technologies for Combating Antibiotic-Resistant Bacteria (CARB). The RPI contains background material and guidance for the preparation of project information papers to the MTEC. Project information papers will be reviewed by the Sponsor and used in a manner that shapes a future MTEC solicitation that requests full project proposals. The results of the project information paper submission will serve as a means to assess the development landscape and potentially focus the proposal effort that will follow. The use of antibiotics saves millions of lives each year around the world. Unfortunately, indiscriminant use and lack of compliance with treatment guidelines have led to conditions for accumulation of mutations in bacteria that have caused drug resistance, resulting in a significant decrease in the number of available drugs effective to treat both rare and common bacterial infections. The rise in antibiotic resistance threatens various aspects of life, including both human and animal health, the agriculture industry, the economy, and the treatment of post-surgical infection from elective and life-saving medical procedures. Therefore, there is a critical need to develop novel antibiotics, other therapeutics, and, vaccines to combat infection by antibiotic-resistant bacteria and improve medical surveillance and diagnostic tests for the identification and characterization of antibiotic-resistant bacteria. Advancement in these areas will hopefully make a major impact by strengthening national and international healthcare for humans and animals, public health, agriculture practices, food safety, and research, development and manufacturing. This MTEC RPI is generally focused on the development of technologies (i.e., biosurveillance, diagnostic tests, antibiotics, vaccines, and other therapeutics) that counter antibiotic-resistance. The use of interdisciplinary approaches including systems biology and synthetic biology to advance prototype development efforts to combat antibiotic resistance are encouraged but not required. Examples of specific areas of interest (not in order of importance) include, but are not limited to: 1. Disease surveillance to detect and control antibiotic-resistance o National and global approaches to coordinate and integrate data across established medical surveillance systems, including laboratory response networks o Robust laboratory platforms for testing resistance and genetic characterization of antibiotic-resistant bacteria o Improved methods or approaches to monitor and control the spread of antibiotic-resistant bacteria in theaters of operation o Technologies or approaches tailored to leverage overseas laboratory assets and capabilities for medical surveillance of antibiotic-resistant bacteria o Enhance ongoing U.S. Department of Defense efforts to maintain a repository of resistant bacteria strains by developing novel advances in specimen collection, storage, and data analysis o Agile new technical or logistical approaches to augment the whole-genome sequencing methods of existing U.S. Department of Defense surveillance efforts, (e.g., the Multidrug-resistant organism Repository and Surveillance Network at Walter Reed Army Institute of Research and the Global Emerging Infectious Disease Surveillance and Response programs) 2. Improved, affordable diagnostics that rapidly detect and/or characterize antibiotic-resistant bacteria o Point-of-need, rapid diagnostic methods that rapidly differentiate between bacterial and viral infections o Point-of-need, rapid diagnostic tests that identify patterns and/or mechanisms of antibiotic resistance to limit the use of antibiotics o Utilization of genetic material (e.g., whole genome sequencing or metagenomics) and/or bioinformatics to develop new diagnostics tests with an open-system architecture compatible with the widest possible range of military-relevant settings from austere point-of-use and mobile, deployed hospitals in theaters of operation through clinical use in fixed-facility military and civilian hospitals worldwide o Novel, culture-based methods that profile and characterize antibiotic resistance 3. Development of novel antibiotic drugs or other non-traditional therapeutics for the treatment of infections caused by antibiotic-resistant bacteria o Novel antibiotics or therapeutic approaches include those that counteract carbapenem resistance that is based on impermeability, efflux pump mechanisms, overexpression of broad-spectrum ß-lactamases, and/or expression of ß-lactamases and other carbapenemase enzymes 4. Development of novel vaccines to prevent the spread of resistant bacteria 5. Advancement of innovative therapeutic approaches to combat or circumvent antibiotic-resistance Efforts to reduce the incidence of drug-resistant infections due to the following bacteria are of particular interest, however, the submission of projects that target other drug-resistant bacteria with military relevance are also encouraged. • Carbapenem-resistant Enterobacteriaceae (CRE) • Carbapenem-resistant Acinetobacter spp. • Methicillin-resistant Staphylococcus aureus (MRSA) • Vancomycin-resistant Enterococcus (VRE) • Other Multidrug-resistant (MDR)-Gram negative strains • Clostridium difficile • Neisseria gonorrhoeae • Multidrug-resistant Pseudomonas spp. • Multidrug-resistant non-typhoidal Salmonella • Multidrug-resistant tuberculosis infections • Antibiotic-resistant invasive pneumococcal disease Project information papers must be submitted by 11:59 pm on April 30, 2017 via email to mtec@mtec-sc.org. Project information papers may be submitted by both MTEC members and non-members. Please note that MTEC membership is required for the submission of a full proposal in response to a future MTEC Request for Project Proposals for CARB. View the RPI at https://mtec-sc.org/active-solicitations/
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/RPI-17-04-CARB/listing.html)
- Record
- SN04480512-W 20170422/170421000418-5f72932cd7da147e482009e9262f27fd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |